Dimensional International Vector Equity ETF

Dimensional International Vector Equity ETF (DXIV) is an actively managed fund. It owns about 2,790 stocks of companies in developed markets outside the US, from large firms like ASML and Roche to small companies. Unlike a plain index fund, it leans toward smaller, cheaper and more profitable companies. That approach costs 0.30% a year, well above the 0.09% average of similar funds, and the fund's record only goes back to its September 2024 launch.

• Over the year to Oct 27, 2026, DXIV returned +19.0%, 1st of 8 among similar funds.
• Its worst full calendar year was 2025 (+39.1%); its best was 2025 (+39.1%).
• The deepest fall in its price history was 13.7% (Mar 19, 2025 to Apr 7, 2025), recovered by Apr 28, 2025.

As of Jul 31, 2026, the fund held 2,790 securities; the ten largest made up 7.13% of assets, and 3.3% sat in cash and money-market holdings.

• Over the three months to Jul 31, 2026, investors added a net $56.8M (creations minus redemptions, per the N-PORT report).
• Monthly total returns reported for that quarter: +2.81%, -2.67%, +3.01%.

DXIV does not track an index. Dimensional Fund Advisors starts with all the non-US developed-market companies it has approved, weighted by market value, so bigger companies get bigger weights. It then sharply raises the fund's exposure to three groups: smaller companies, "value" stocks that trade at a low price compared with book value (a company's net worth on its balance sheet), and highly profitable companies. Mostly it does this by holding less of large, expensive or less profitable firms, or by not purchasing them at all. The fund measures itself against the MSCI World ex USA IMI Index.

The managers also adjust positions for shorter-term signals, such as price momentum. They trade flexibly to keep costs down rather than rebalancing on a fixed schedule. The prospectus filed February 27, 2026, reported portfolio turnover of 8%, which means only a small share of the portfolio changed hands. As of July 31, 2026, the fund held about 2,790 stocks. The 10 largest made up just 7.1% of assets, led by ASML, Roche and Shell.

At least 80% of net assets go into stocks. The fund may use futures to manage cash coming in and going out, buy depositary receipts (shares of foreign companies traded on other exchanges), and lend its securities for extra income. The prospectus describes currency forwards only for settling trades and moving cash between currencies. That means holders feel the swings of foreign currencies against the US dollar.

• DXIV charges 0.3% a year, versus an average of 0.09% for the similar funds below (7th of 8, cheapest first).
• Of that, 0.25% is the management fee; the rest covers other fund expenses.
• The fee includes a 0.23% waiver from the adviser, which may end.
• Using the prospectus's standard example, $10,000 invested would cost about $31 in the first year and $643 over 10 years (assuming a 5% annual return).

It adds broad exposure to developed-market stocks outside the US, tilted toward smaller, value and profitable companies, which can balance a portfolio heavy in US stocks.

As of July 31, 2026, Japan made up 24.9% of DXIV's assets, Canada 12.2% and the UK 10.2%. That gives a US-heavy portfolio exposure to other economies and currencies. The record is short, though. The fund launched in September 2024, so it was not around for the 2008, 2020 or 2022 downturns. Its only full calendar year, 2025, returned 38.5%. Its deepest drop was 13.7%, from March 19 to April 7, 2025, and it recovered by April 28. A brief dip like that tells you little about how a fund tilted toward small and value stocks might hold up in a long bear market. That matters if you may need to sell shares in a bad year. The yield was 2.42% as of October 27, 2026, paid quarterly. Under the SEC's standard example, costs on $10,000 come to $643 over 10 years. Past results don't predict the future, and a plan should look at the whole portfolio, not one fund.

Matched by holdings overlap from the latest N-PORT reports.